American Society of Hematology

SHERPA: Blue

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Levine
    Levine
  3. Derkach
    Derkach
  4. Gonen
    Gonen
  5. Stein
    Stein
  6. Dogan
    Dogan
  7. Zelenetz
    Zelenetz
  8. Bewersdorf
    Bewersdorf
  9. Chadha
    Chadha
  10. Devlin
    Devlin

Groups

  1. Center for Hematologic Malignancies (15)
  2. Department of Medicine (15)
  3. Epidemiology and Biostatistics (15)
  4. Executive Committee, Center for Hematologic Malignancies (15)
  5. GSK Faculty (15)
  6. Hematologic Malignancies, Division of (15)
  7. Human Oncology and Pathogenesis Program (15)
  8. Tow Center for Developmental Oncology (TCDO) (15)
  9. Biostatistics Service (14)
  10. Adult Leukemia (13)
Search Within
  1. "Meeting abstract"
  2. "Human Oncology and Pathogenesis Program"
  3. "Omar Abdel-Wahab"
  4. "Blood"
  5. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (15)
Groups
  1. Center for Hematologic Malignancies (15)
  2. Department of Medicine (15)
  3. Epidemiology and Biostatistics (15)
  4. Executive Committee, Center for Hematologic Malignancies (15)
  5. GSK Faculty (15)
  6. Hematologic Malignancies, Division of (15)

More Groups

People
  1. Omar Abdel-Wahab (15)
  2. Ross Levine (9)
  3. Martin Tallman (7)
  4. Andriy Derkach (5)
  5. Eytan Stein (5)
  6. Mithat Gonen (5)

More People

Years
  1. 2023 (2)
  2. 2022 (2)
  3. 2021 (2)
  4. 2020 (2)
  5. 2015 (1)
  6. 2014 (3)

More Years

Publications
  1. Blood (15)

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • E7820, an anti-cancer sulfonamide, in combination with venetoclax in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Meeting Abstract

    Bewersdorf, J. P.; Chandhok, N. S.; Watts, J. M.; Derkach, A.; Abdel-Wahab, O.; Stein, E. M.; Taylor, J.
    Blood (2023)

    Fulltext@MSK | Save
  • Immune escape after allogeneic hematopoietic cell transplantation in pediatric patients with acute myeloid leukemia
    Meeting Abstract

    Shahid, S.; Ceglia, N.; Le Luduec, J. B.; McPherson, A.; Spitzer, B.; Bojilova, V.; Panjwani, M. K.; Roshal, M.; Shah, S.; Abdel-Wahab, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes
    Meeting Abstract

    Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia
    Meeting Abstract

    Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Hairy cell leukemia variant has similar survival to classical disease despite poorer responses to initial therapy: A 30-year experience from Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Getta, B.; Woo, K. M.; Devlin, S.; Park, J. H.; Abdel-Wahab, O.; Tallman, M. S.
    Blood (2015)

    Fulltext@MSK | Save
  • Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia
    Meeting Abstract

    Walter, R. B.; Othus, M.; Paietta, E. M.; Racevskis, J.; Fernandez, H. F.; Lee, J. W.; Sun, Z. X.; Tallman, M. S.; Patel, J. P.; Gonen, M.; more...
    Blood (2014)

    Fulltext@MSK | Save